Results 221 to 230 of about 9,786 (244)
Some of the next articles are maybe not open access.
American Journal of Health-System Pharmacy, 2007
The pharmacology, clinical efficacy, adverse effects and toxicities, and the economic issues that should be considered in using deferasirox are reviewed.Iron overload is a complication of the chronic blood transfusions used to treat several hematologic disorders. To date, management of transfusional iron overload has consisted of chelation therapy with
openaire +4 more sources
The pharmacology, clinical efficacy, adverse effects and toxicities, and the economic issues that should be considered in using deferasirox are reviewed.Iron overload is a complication of the chronic blood transfusions used to treat several hematologic disorders. To date, management of transfusional iron overload has consisted of chelation therapy with
openaire +4 more sources
Deferasirox versus deferoxamine
Blood, 2006Cappellini and colleagues[1][1] recently published the results of the first large, randomized phase 3 trial comparing deferoxamine (DFO) and deferasirox, a trial designed to demonstrate the efficacy of deferasirox in regularly transfused patients with β-thalassemia.
Michael Gary Martin, Murat O. Arcasoy
openaire +2 more sources
Benzoxazinone Intermediate for the Synthesis of Deferasirox. Preparation of Deferasirox
Organic Preparations and Procedures International, 2015Deferasirox (Exjade, ICL-670A), 4-[3,5-bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl]benzoic acid (6), is an iron chelator developed for the treatment of chronic iron overload in patients who are rece...
Onsiri Srikun +2 more
openaire +2 more sources
Fanconi Syndrome Due to Deferasirox
American Journal of Kidney Diseases, 2009Deferasirox is an innovative iron-chelating treatment. However, preliminary data have suggested that kidney toxicity may be a major issue in the management of patients receiving this drug. We report a case of Fanconi syndrome associated with acute renal insufficiency in a patient receiving deferasirox.
Richard Delarue +9 more
openaire +3 more sources
Hemoglobin, 2009
Cumulative data from prospective studies in over 3,000 patients with a range of transfusion dependent anemias have established key principles about the efficacy and safety of deferasirox (DFS). Pivotal preregistration studies established the relationship between dose, iron excretion, and tolerability using changes in liver iron concentration (LIC) to ...
openaire +3 more sources
Cumulative data from prospective studies in over 3,000 patients with a range of transfusion dependent anemias have established key principles about the efficacy and safety of deferasirox (DFS). Pivotal preregistration studies established the relationship between dose, iron excretion, and tolerability using changes in liver iron concentration (LIC) to ...
openaire +3 more sources
Deferasirox: pharmacokinetics and clinical experience
Expert Opinion on Drug Metabolism & Toxicology, 2011Iron overload is an inevitable consequence of transfusion therapy for a variety of underlying anemias. Iron overload, without effective chelation, will lead to significant morbidity and mortality. Deferasirox (Exjade®) is an oral tridentate iron chelator used for reducing iron overload.In addition to the pharmacokinetic and pharmacodynamic profile of ...
GALANELLO, RENZO +2 more
openaire +3 more sources
Clinical Pharmacology of Deferasirox
Clinical Pharmacokinetics, 2014Iron accumulation is a consequence of regular red cell transfusions, and can occur as a result of ineffective erythropoiesis secondary to increased intestinal iron absorption, in patients with various anemias. Without appropriate treatment, iron overload can lead to increased morbidity and mortality.
openaire +3 more sources
Deferasirox nephrotoxicity—the knowns and unknowns
Nature Reviews Nephrology, 2014In 2005, the oral iron chelator deferasirox was approved by the FDA for clinical use as a first-line therapy for blood-transfusion-related iron overload. Nephrotoxicity is the most serious and frequent adverse effect of deferasirox treatment. This nephrotoxicity can present as an acute or chronic decrease in glomerular filtration rate (GFR).
Juan Daniel Díaz-García +5 more
openaire +3 more sources
Hospital Pharmacy, 2006
The increasing complexity of cancer chemotherapy heightens the requirement that pharmacists be familiar with these highly toxic agents. This column will review various issues related to preparation, dispensing, and administration of cancer chemotherapy.
Leonard Wryter +2 more
openaire +2 more sources
The increasing complexity of cancer chemotherapy heightens the requirement that pharmacists be familiar with these highly toxic agents. This column will review various issues related to preparation, dispensing, and administration of cancer chemotherapy.
Leonard Wryter +2 more
openaire +2 more sources
Case of presymptomatic aceruloplasminemia treated with deferasirox
Hepatology Research, 2014Aceruloplasminemia is an autosomal recessive disease characterized by an abnormal iron metabolism. The absence of ferroxidase activity caused by mutation of ceruloplasmin leads to iron overload in the brain, liver and other organs. We report a 35‐year‐old man who was diagnosed with aceruloplasminemia without neurological manifestation despite the ...
Masaru Harada +8 more
openaire +3 more sources